Free tool
Find any stock
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
Search all ~22,000 companies we cover across the US, Europe and Asia-Pacific, or browse them market by market — then open any one of them for the full analysis.
268 stocks worldwide match these filters · market cap, largest first. Clear filters
Data as of Aug 27, 2026 · updates nightly, Mon–Sat
| Ticker | Company | Theme | Market cap (USD) | Price | vs 52-week high | 1M return |
|---|---|---|---|---|---|---|
| KMDA | Kamada Ltd. Ordinary Shares | Rare disease | $483.48M | $8.38 | −10.37% | +18.70% |
| QTTB | Q32 Bio Inc. | Rare disease | $481.67M | $16.18 | −31.35% | +2.99% |
| AVIR | Atea Pharmaceuticals, Inc. | Rare disease | $441.93M | $5.51 | −14.57% | +22.17% |
| LRMR | Larimar Therapeutics, Inc. | Rare disease |
Every company we cover sits in at least one of these lists. Each one opens as a full table of its members, ordered by market value.
The 11 business sectors every covered company is classified into.
The 20 narrower groupings we keep for parts of the market that do not split neatly by sector.
Price chart, technicals, money flow, fundamentals and an AI-written read — one page per stock, $9.90 each. Already know the symbol?
| $432.15M |
| $4.17 |
| −35.05% |
| +8.88% |
| XFOR | X4 Pharmaceuticals, Inc. | Rare disease | $412.45M | $4.17 | −13.66% | +6.11% |
| ENTA | Enanta Pharmaceuticals, Inc. | Rare disease | $412.12M | $14.15 | −17.49% | +12.21% |
| 4552.T | JCR Pharmaceuticals Co., Ltd. | Rare disease | $406.58M | 531.00 JPY | −35.56% | +2.71% |
| UPB | Upstream Bio, Inc. | Rare disease | $390.52M | $7.13 | −78.83% | +11.41% |
| IFRX | InflaRx N.V. | Rare disease | $356.63M | $2.42 | −17.94% | +43.20% |
| IKT | Inhibikase Therapeutics, Inc. | Rare disease | $347.44M | $2.49 | −1.97% | +7.79% |
| CUV.AX | Clinuvel Pharmaceuticals Limited | Rare disease | $338.48M | 9.36 AUD | −33.14% | −2.40% |
| PRQR | ProQR Therapeutics N.V. | Rare disease | $331.63M | $2.35 | −24.19% | +33.52% |
| TRDA | Entrada Therapeutics, Inc. | Rare disease | $296.70M | $7.00 | −57.45% | +20.07% |
| FULC | Fulcrum Therapeutics, Inc. | Rare disease | $294.51M | $3.86 | −75.48% | +3.76% |
| TTRX | Turn Therapeutics Inc. | Rare disease | $292.44M | $9.63 | −63.66% | +25.06% |
| SION | Sionna Therapeutics, Inc. | Rare disease | $282.58M | $6.17 | −88.78% | −86.75% |
| ELDN | Eledon Pharmaceuticals, Inc. | Rare disease | $272.22M | $3.35 | −27.17% | −1.47% |
| 0OB3.L | Valneva SE | Rare disease | $270.41M | 2.87 EUR | −46.23% | +0.75% |
| IVVD | Invivyd, Inc. | Rare disease | $265.78M | $0.90 | −70.63% | +52.06% |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | Rare disease | $263.56M | $4.20 | −45.81% | +22.81% |
| SLGL | Sol-Gel Technologies Ltd. | Rare disease | $260.05M | $79.43 | −18.92% | −4.38% |
| XUP.DE | Genfit S.A. | Rare disease | $258.22M | 14.08 EUR | −1.81% | −1.81% |
| 0QN1.L | Santhera Pharmaceuticals Holding AG | Rare disease | $254.58M | 15.66 CHF | −16.35% | −1.88% |
| AKBA | Akebia Therapeutics, Inc. | Rare disease | $251.20M | $0.91 | −72.70% | −28.62% |
| CRDL | Cardiol Therapeutics Inc. | Rare disease | $250.00M | $2.14 | −5.93% | +78.33% |
| CRDL.TO | Cardiol Therapeutics Inc. | Rare disease | $249.99M | 2.97 CAD | −5.71% | +74.71% |
| 0T6G.L | Q32 Bio Inc. | Rare disease | $246.69M | $16.34 | −30.47% | +7.94% |
| PEPG | PepGen Inc. | Rare disease | $237.21M | $3.22 | −58.72% | +75.96% |
| RNA | Prosensa Holding B.V. Ordinary Shares | Rare disease | $236.91M | $13.85 | −17.41% | +20.54% |
| SIGA | SIGA Technologies, Inc. | Rare disease | $220.58M | $3.07 | −67.51% | −8.08% |
| KROS | Keros Therapeutics, Inc. | Rare disease | $220.48M | $11.12 | −50.69% | +10.43% |
| ANTX | AN2 Therapeutics, Inc. | Rare disease | $208.68M | $5.53 | −23.09% | +17.66% |
| ARMP | Armata Pharmaceuticals, Inc. | Rare disease | $202.64M | $5.45 | −66.65% | +15.22% |
| MSCL.TO | Satellos Bioscience Inc. | Rare disease | $199.95M | 13.08 CAD | −31.09% | −2.10% |
| PLX | Protalix BioTherapeutics, Inc. | Rare disease | $199.82M | $2.48 | −22.26% | +6.44% |
| MSLE | Satellos Bioscience Inc. | Rare disease | $198.59M | $9.36 | −30.12% | −1.06% |
| 0AB6.L | Hyloris Pharmaceuticals SA | Rare disease | $185.32M | 4.38 EUR | −46.72% | −1.79% |
| SPRB | Spruce Biosciences, Inc. | Rare disease | $176.69M | $61.48 | −74.38% | +47.79% |
| MDWD | MediWound Ltd. | Rare disease | $163.96M | $12.70 | −37.44% | −13.13% |
| EQ | Equillium, Inc. | Rare disease | $149.64M | $2.36 | −33.33% | +1.72% |
| AARD | Aardvark Therapeutics, Inc. | Rare disease | $149.04M | $6.81 | −62.04% | +6.07% |
| UNCY | Unicycive Therapeutics, Inc. | Rare disease | $148.74M | $5.43 | −37.87% | +9.92% |
| CRNO-B.ST | Cereno Scientific AB (publ) | Rare disease | $148.23M | 4.71 SEK | −57.60% | +0.13% |
| MIST | Milestone Pharmaceuticals Inc. | Rare disease | $146.91M | $1.18 | −61.44% | +10.28% |
| 4599.T | StemRIM | Rare disease | $140.21M | 350.00 JPY | −4.89% | +21.53% |
| INO | Inovio Pharmaceuticals, Inc. | Rare disease | $134.42M | $1.30 | −56.38% | +26.21% |
| CPIX | Cumberland Pharmaceuticals Inc. | Rare disease | $130.35M | $8.97 | −3.34% | +69.86% |
| DXB.AX | Dimerix Limited | Rare disease | $122.97M | 0.29 AUD | −56.39% | +20.83% |
| 0H8T.L | Aclaris Therapeutics, Inc. | Rare disease | $122.82M | $6.14 | −6.69% | −6.69% |
| RFL | Rafael Holdings, Inc. | Rare disease | $119.08M | $2.29 | −42.17% | +9.05% |
| MDP.TO | Medexus Pharmaceuticals Inc. | Rare disease | $117.29M | 5.18 CAD | −5.82% | +7.02% |
| PYPD | PolyPid Ltd. | Rare disease | $103.79M | $5.11 | −10.82% | +36.27% |
| PTHS | Pelthos Therapeutics Inc. | Rare disease | $102.53M | $26.78 | −28.59% | −3.56% |
| ABNX.PA | ABIONYX Pharma SA | Rare disease | $98.59M | 1.97 EUR | −62.68% | +5.79% |
| 0RAG.L | ABIONYX Pharma SA | Rare disease | $95.77M | 2.01 EUR | −62.00% | +3.40% |
| ILA.AX | Island Pharmaceuticals Limited | Rare disease | $95.70M | 0.45 AUD | −28.57% | +18.42% |
| FBIO | Fortress Biotech, Inc. | Rare disease | $94.38M | $2.81 | −37.97% | −17.11% |
| PLYX | Polaryx Therapeutics, Inc. | Rare disease | $94.21M | $2.09 | −95.73% | +5.03% |
| PAR.AX | Paradigm Biopharmaceuticals Limited | Rare disease | $92.46M | 0.22 AUD | −54.26% | +30.30% |
| RLYB | Rallybio Corporation | Rare disease | $89.64M | $16.88 | −3.95% | +4.49% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.
Size bands, from the largest companies down to the smallest we cover.
The 23 listing venues our coverage spans, across the Americas, Europe and Asia-Pacific.
5 lists built on a single stated criterion, such as paying a dividend or trading near a 52-week high.
The largest one day percentage moves in either direction, among the mid, large and mega cap companies we cover.